1. Home
  2. GNFT vs SWKH Comparison

GNFT vs SWKH Comparison

Compare GNFT & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNFT
  • SWKH
  • Stock Information
  • Founded
  • GNFT 1999
  • SWKH 1996
  • Country
  • GNFT France
  • SWKH United States
  • Employees
  • GNFT N/A
  • SWKH N/A
  • Industry
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • SWKH Diversified Financial Services
  • Sector
  • GNFT Health Care
  • SWKH Finance
  • Exchange
  • GNFT Nasdaq
  • SWKH Nasdaq
  • Market Cap
  • GNFT 172.2M
  • SWKH 201.5M
  • IPO Year
  • GNFT 2019
  • SWKH 1999
  • Fundamental
  • Price
  • GNFT $3.47
  • SWKH $16.39
  • Analyst Decision
  • GNFT Strong Buy
  • SWKH
  • Analyst Count
  • GNFT 1
  • SWKH 0
  • Target Price
  • GNFT $13.00
  • SWKH N/A
  • AVG Volume (30 Days)
  • GNFT 6.9K
  • SWKH 8.6K
  • Earning Date
  • GNFT 09-19-2024
  • SWKH 11-14-2024
  • Dividend Yield
  • GNFT N/A
  • SWKH N/A
  • EPS Growth
  • GNFT N/A
  • SWKH N/A
  • EPS
  • GNFT 0.47
  • SWKH 0.84
  • Revenue
  • GNFT $86,225,222.00
  • SWKH $24,725,000.00
  • Revenue This Year
  • GNFT $145.20
  • SWKH N/A
  • Revenue Next Year
  • GNFT N/A
  • SWKH $6.17
  • P/E Ratio
  • GNFT $7.23
  • SWKH $19.54
  • Revenue Growth
  • GNFT 175.45
  • SWKH N/A
  • 52 Week Low
  • GNFT $3.33
  • SWKH $15.14
  • 52 Week High
  • GNFT $6.42
  • SWKH $18.49
  • Technical
  • Relative Strength Index (RSI)
  • GNFT 31.89
  • SWKH 53.54
  • Support Level
  • GNFT $3.35
  • SWKH $16.25
  • Resistance Level
  • GNFT $3.57
  • SWKH $16.64
  • Average True Range (ATR)
  • GNFT 0.11
  • SWKH 0.35
  • MACD
  • GNFT 0.01
  • SWKH 0.05
  • Stochastic Oscillator
  • GNFT 21.82
  • SWKH 78.07

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

Share on Social Networks: